Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

77 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Strategies for In Vivo Screening and Mitigation of Hepatotoxicity Associated with Antisense Drugs.
Kamola PJ, Maratou K, Wilson PA, Rush K, Mullaney T, McKevitt T, Evans P, Ridings J, Chowdhury P, Roulois A, Fairchild A, McCawley S, Cartwright K, Gooderham NJ, Gant TW, Moores K, Hughes SA, Edbrooke MR, Clark K, Parry JD. Kamola PJ, et al. Among authors: moores k. Mol Ther Nucleic Acids. 2017 Sep 15;8:383-394. doi: 10.1016/j.omtn.2017.07.003. Epub 2017 Jul 8. Mol Ther Nucleic Acids. 2017. PMID: 28918038 Free PMC article.
In silico and in vitro evaluation of exonic and intronic off-target effects form a critical element of therapeutic ASO gapmer optimization.
Kamola PJ, Kitson JD, Turner G, Maratou K, Eriksson S, Panjwani A, Warnock LC, Douillard Guilloux GA, Moores K, Koppe EL, Wixted WE, Wilson PA, Gooderham NJ, Gant TW, Clark KL, Hughes SA, Edbrooke MR, Parry JD. Kamola PJ, et al. Among authors: moores k. Nucleic Acids Res. 2015 Oct 15;43(18):8638-50. doi: 10.1093/nar/gkv857. Epub 2015 Sep 3. Nucleic Acids Res. 2015. PMID: 26338776 Free PMC article.
Pharmacological Characterization of a Novel ENaCα siRNA (GSK2225745) With Potential for the Treatment of Cystic Fibrosis.
Clark KL, Hughes SA, Bulsara P, Coates J, Moores K, Parry J, Carr M, Mayer RJ, Wilson P, Gruenloh C, Levin D, Darton J, Weber WM, Sobczak K, Gill DR, Hyde SC, Davies LA, Pringle IA, Sumner-Jones SG, Jadhav V, Jamison S, Strapps WR, Pickering V, Edbrooke MR. Clark KL, et al. Among authors: moores k. Mol Ther Nucleic Acids. 2013 Jan 15;2(1):e65. doi: 10.1038/mtna.2012.57. Mol Ther Nucleic Acids. 2013. PMID: 23322014 Free PMC article.
The discovery of SB-435495. A potent, orally active inhibitor of lipoprotein-associated phospholipase A(2) for evaluation in man.
Blackie JA, Bloomer JC, Brown MJ, Cheng HY, Elliott RL, Hammond B, Hickey DM, Ife RJ, Leach CA, Lewis VA, Macphee CH, Milliner KJ, Moores KE, Pinto IL, Smith SA, Stansfield IG, Stanway SJ, Taylor MA, Theobald CJ, Whittaker CM. Blackie JA, et al. Bioorg Med Chem Lett. 2002 Sep 16;12(18):2603-6. doi: 10.1016/s0960-894x(02)00473-0. Bioorg Med Chem Lett. 2002. PMID: 12182870
The identification of clinical candidate SB-480848: a potent inhibitor of lipoprotein-associated phospholipase A2.
Blackie JA, Bloomer JC, Brown MJ, Cheng HY, Hammond B, Hickey DM, Ife RJ, Leach CA, Lewis VA, Macphee CH, Milliner KJ, Moores KE, Pinto IL, Smith SA, Stansfield IG, Stanway SJ, Taylor MA, Theobald CJ. Blackie JA, et al. Bioorg Med Chem Lett. 2003 Mar 24;13(6):1067-70. doi: 10.1016/s0960-894x(03)00058-1. Bioorg Med Chem Lett. 2003. PMID: 12643913
In vivo activity of an azole series of CCR2 antagonists.
Smethurst CA, Bevan N, Brooks C, Emmons A, Gough PJ, Mookherjee C, Moores K, Peace S, Philp J, Piercy V, Watson SP, Zippoli M. Smethurst CA, et al. Among authors: moores k. Bioorg Med Chem Lett. 2012 Dec 1;22(23):7252-5. doi: 10.1016/j.bmcl.2012.09.020. Epub 2012 Sep 23. Bioorg Med Chem Lett. 2012. PMID: 23079519
Identification of a sulfonamide series of CCR2 antagonists.
Peace S, Philp J, Brooks C, Piercy V, Moores K, Smethurst C, Watson S, Gaines S, Zippoli M, Mookherjee C, Ife R. Peace S, et al. Among authors: moores k. Bioorg Med Chem Lett. 2010 Jul 1;20(13):3961-4. doi: 10.1016/j.bmcl.2010.04.142. Epub 2010 May 7. Bioorg Med Chem Lett. 2010. PMID: 20627722
N-1 substituted pyrimidin-4-ones: novel, orally active inhibitors of lipoprotein-associated phospholipase A2.
Boyd HF, Fell SC, Flynn ST, Hickey DM, Ife RJ, Leach CA, Macphee CH, Milliner KJ, Moores KE, Pinto IL, Porter RA, Rawlings DA, Smith SA, Stansfield IG, Tew DG, Theobald CJ, Whittaker CM. Boyd HF, et al. Among authors: moores ke. Bioorg Med Chem Lett. 2000 Nov 20;10(22):2557-61. doi: 10.1016/s0960-894x(00)00510-2. Bioorg Med Chem Lett. 2000. PMID: 11086729
Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor.
MacPhee CH, Moores KE, Boyd HF, Dhanak D, Ife RJ, Leach CA, Leake DS, Milliner KJ, Patterson RA, Suckling KE, Tew DG, Hickey DM. MacPhee CH, et al. Among authors: moores ke. Biochem J. 1999 Mar 1;338 ( Pt 2)(Pt 2):479-87. Biochem J. 1999. PMID: 10024526 Free PMC article.
77 results